title: Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?
authors.forename: Ana E
authors.initials: AE
authors.lastname: Sirvent
authors.forename: Ricardo
authors.initials: R
authors.lastname: Enríquez
authors.forename: María
authors.initials: M
authors.lastname: Sánchez
authors.forename: César
authors.initials: C
authors.lastname: González
authors.forename: Isabel
authors.initials: I
authors.lastname: Millán
authors.forename: Francisco
authors.initials: F
authors.lastname: Amorós
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D000075202:Contraindications; D000069448:Denosumab / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000139:chemically induced*; D006996:Hypocalcemia / Q000139:chemically induced*; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D012720:Severity of Illness Index
chemical_list: D050071:Bone Density Conservation Agents; D000069448:Denosumab